Merck & Co., Inc. is 143.0x more valuable than Immunome Inc. by market capitalization ($294.13 B vs $2.06 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | IMNM | MRK |
|---|---|---|
| Market cap | $2.06 B | $294.13 B |
| US-listed rank | #2083 | #44 |
| Revenue (latest FY) | $6.94M | $65.01B |
| Net income (latest FY) | -$212.39M | $18.25B |
| Net margin | -3060.0% | 28.1% |
| P/E (trailing FY) | - | 16.1 |
| SEC filings | 416 | 996 |
Merck & Co., Inc. is 143.0x more valuable than Immunome Inc. by market capitalization ($294.13 B vs $2.06 B).
In their latest fiscal years, Immunome Inc. reported $6.94M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Immunome Inc. and Merck & Co., Inc., or browse the full rankings.